Polymer Capital Management (Us) LLC Alnylam Pharmaceuticals, Inc. Transaction History
Polymer Capital Management (Us) LLC
- $945 Billion
- Q3 2025
A detailed history of Polymer Capital Management (Us) LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Polymer Capital Management (Us) LLC holds 808 shares of ALNY stock, worth $362,921. This represents 0.04% of its overall portfolio holdings.
Number of Shares
808Holding current value
$362,921% of portfolio
0.04%Shares
2 transactions
Others Institutions Holding ALNY
# of Institutions
917Shares Held
117MCall Options Held
1.25MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA16.4MShares$7.38 Billion1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$6.09 Billion0.1% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.29 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.22MShares$3.24 Billion0.65% of portfolio
-
Jpmorgan Chase & CO New York, NY4.54MShares$2.04 Billion0.14% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $55.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...